VitriVax Receives $5M Grant for Vaccine Development

VitriVax, Inc., a formulation technology company, announced today a $5M two-year grant from the Bill & Melinda Gates Foundation.

The grant will allow the company to develop further its proprietary single shot, thermostabilization vaccine technology (ALTAtm) and begin the development of pilot-scale manufacturing capacity. As part of the grant, the company will study the ALTAtm mechanism of action using model antigens, such as those targeting HIV.

The project will focus on formulation development, preclinical studies, and the development of Good Manufacturing Practice protocols to support future regulatory submissions.

"VitriVax, with funding from the Bill & Melinda Gates Foundation, is taking an important step forward in establishing its vaccine technology," said Romulo Colindres, CEO of VitriVax. "We are honored by the foundation's support of our efforts to advance equitable access to vaccines around the world."

About VitriVax

VitriVax, headquartered in Boulder, CO, has engineered its proprietary Atomic Layering Thermostable Antigen and Adjuvant (ALTAtm) technology platform to enable thermostable, single-shot vaccines across a broad range of indications while maintaining or potentially even enhancing the immune response of vaccines. ALTAtm can be applied to a wide variety of vaccine antigens and adjuvants to protect against thermal and chemical degradation and enable controlled release, incorporating prime doses and additional booster doses in a single-shot administration. These technologies may also facilitate the co-formulation of multiple, otherwise incompatible, antigens in a single injection.